ArticleSeminars in arthritis and rheumatism2017
Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015.
Article in Seminars in arthritis and rheumatism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Tocilizumab for giant cell arteritis.The Cochrane database of systematic reviews · 2022Pooled it
- Tocilizumab for giant cell arteritis.The Cochrane database of systematic reviews · 2021Pooled it
- Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.Arthritis research & therapy · 2019Trial
- Diagnostic accuracy ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Frequency, diagnosis, and pharmacological treatment of giant cell arteritis in Germany: database analysis of medical insurance data.Therapeutic advances in musculoskeletal disease · 2026Article
- Frequency, diagnosis, and management of polymyalgia rheumatica in Germany-database analysis of medical insurance data.Rheumatology (Oxford, England) · 2025Article
- Physiotherapy for the Management of Polymyalgia Rheumatica: Results From a UK Cross-Sectional Survey.Musculoskeletal care · 2025Article
- Prevalence and Clinical Characteristics of Vasculitis in the Alaska Native and American Indian Peoples of Alaska.Arthritis care & research · 2025Article
- Article
- Illness Burden and Unmet Patient Needs in Giant Cell Arteritis: Current State and Future Prospects.Open access rheumatology : research and reviews · 2025Review
- Positron Emission Tomography/Computed Tomography in Polymyalgia Rheumatica: When and for What-A Critical Review.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Immunology of Giant Cell Arteritis.Circulation research · 2023Review
- Giant-cell arteritis related strokes: scoping review of mechanisms and rethinking treatment strategy?Frontiers in neurology · 2023Article
- Prevalence of frailty in patients with polymyalgia rheumatica and association with health-related quality of life, cognition and sarcopenia.Rheumatology (Oxford, England) · 2022Article
- An update on polymyalgia rheumatica.Journal of internal medicine · 2022Review
- Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.Arthritis research & therapy · 2022Article
- The Impact of High Dose Glucocorticoids on Bone Health and Fracture Risk in Systemic Vasculitides.Frontiers in endocrinology · 2022Review
- Global epidemiology of vasculitis.Nature reviews. Rheumatology · 2022Review
- Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden-an update on incidence and first prevalence estimate.Rheumatology (Oxford, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThere are no estimates of the prevalence of giant cell arteritis (GCA) or polymyalgia rheumatica (PMR) in a US population in the current millennium. The purpose of this study was to estimate the 2015 prevalence of GCA and PMR in a US population-based setting.
methodsCohorts of incident GCA in 1950-2009 and incident PMR in 1970-2014 were previously identified among residents of Olmsted County, Minnesota. Prevalence estimates were obtained from the age-, sex-, and calendar year-specific incidence rates and adjusted to the US white 2010 population aged ≥50 years. Confidence intervals (CI) were computed using bootstrap sampling.
resultsThere were 248 incident cases of GCA in 1950-2009 and 790 cases of PMR in 1970-2014. The overall age- and sex-adjusted prevalence rate of GCA on January 1, 2015 was 204 (95% CI: 161-254) per 100,000 population aged ≥50 years. GCA prevalence rate in women was 304 (95% CI: 229-375) and in men was 91 (95% CI: 46-156) per 100,000 population. The overall age and sex adjusted prevalence rate of PMR on January 1, 2015 was 701 (95% CI: 651-750) per 100,000 population. PMR prevalence rate in women was 870 (95% CI: 787-957) and in men was 508 (95% CI: 426-589) per 100,000 population.
conclusionPrevalence rates of GCA and PMR in 2015 are similar to previously published prevalence estimates in the late 1990s. The health burden of these diseases among older persons continues to be substantial and reflects the need for continued efforts to better manage it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.